Iron deficiency anemia.
The prevalence of iron deficiency anemia is 2 percent in adult men, 9 to 12 percent in non-Hispanic white women, and nearly 20 percent in black and Mexican-American women. Nine percent of patients older than 65 years with iron deficiency anemia have a gastrointestinal cancer when evaluated. The U.S. Preventive Services Task Force currently recommends screening for iron deficiency anemia in pregnant women but not in other groups. Routine iron supplementation is recommended for high-risk infants six to 12 months of age. Iron deficiency anemia is classically described as a microcytic anemia. The differential diagnosis includes thalassemia, sideroblastic anemias, some types of anemia of chronic disease, and lead poisoning. Serum ferritin is the preferred initial diagnostic test. Total iron-binding capacity, transferrin saturation, serum iron, and serum transferrin receptor levels may be helpful if the ferritin level is between 46 and 99 ng per mL (46 and 99 mcg per L); bone marrow biopsy may be necessary in these patients for a definitive diagnosis. In children, adolescents, and women of reproductive age, a trial of iron is a reasonable approach if the review of symptoms, history, and physical examination are negative; however, the hemoglobin should be checked at one month. If there is not a 1 to 2 g per dL (10 to 20 g per L) increase in the hemoglobin level in that time, possibilities include malabsorption of oral iron, continued bleeding, or unknown lesion. For other patients, an endoscopic evaluation is recommended beginning with colonoscopy if the patient is older than 50.
Killip
Shersten
S
Department of Family and Community Medicine, University of Kentucky, Lexington, Kentucky, USA.
Bennett
John M
JM
Chambers
Mara D
MD
D000284:Administration, Oral; D000465:Algorithms; D018798:Anemia, Iron-Deficiency / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D003937:Diagnosis, Differential; D005260:Female; D005290:Ferric Compounds / Q000627:therapeutic use; D005293:Ferritins / Q000097:blood; D006801:Humans; D007263:Infusions, Parenteral; D007501:Iron / Q000627:therapeutic use*; D008297:Male; D012307:Risk Factors; D014168:Transferrin / Q000032:analysis
D005290:Ferric Compounds; D014168:Transferrin; D005293:Ferritins; D007501:Iron